Literature DB >> 10411262

Mechanisms of pyrazinamide resistance in mycobacteria: importance of lack of uptake in addition to lack of pyrazinamidase activity.

C Raynaud1, M A Lanéelle, R H Senaratne, P Draper, G Lanéelle, M Daffé.   

Abstract

Mycobacteria are known to acquire resistance to the antituberculous drug pyrazinamide (PZA) through mutations in the gene encoding pyrazinamidase (PZase), an enzyme that converts PZA into pyrazinoic acid, the presumed active form of PZA against bacteria. Additional mechanisms of resistance to the drug are known to exist but have not been fully investigated. Among these is the non-uptake of the pro-drug, a possibility investigated in the present study. The uptake mechanism of PZA, a requisite step for the activation of the pro-drug, was studied in Mycobacterium tuberculosis. The incorporation of [14C]PZA by the bacilli was followed in both neutral and acidic environments since PZA activity is known to be optimal at acidic pH. By using a protonophore (carbonyl cyanide m-chlorophenylhydrazone; CCCP), valinomycin, arsenate and low temperature, it was shown that an ATP-dependent transport system is involved in the uptake of PZA. Whilst the structurally analogous compound nicotinamide inhibited the transport system of PZA, other structurally related compounds such as pyrazinoic acid, isoniazid and cytosine did not. Acidic conditions were also without effect. Based on diffusion experiments in liposomes, it was found that PZA diffuses rapidly through membrane bilayers, faster than glycerol, whilst the presence of OmpATb, the porin-like protein of M. tuberculosis, in proteoliposomes slightly increased the diffusion of the drug. This finding may explain why the cell wall mycolate hydrophobic layer does not represent the limiting step in the diffusion of PZA, as judged from comparative experiments using a M. tuberculosis strain and its isogenic mutant elaborating 40% less covalently linked mycolates. PZase activity, and PZA uptake and susceptibility in different mycobacterial species were compared. M. tuberculosis, a naturally PZA-susceptible species, was the only species that exhibited both PZase activity and PZA uptake; no such correlation was observed with the four naturally resistant species examined. Mycobacterium smegmatis possessed a functional PZase but did not take up PZA; the reverse was true for the PZase-negative strain of Mycobacterium avium used, with PZA uptake comparable to that of M. tuberculosis. Mycobacterium bovis BCG and Mycobacterium kansasii exhibited neither a PZase activity nor PZA uptake. These data clearly demonstrate that one of the mechanisms of resistance to PZA resides in the failure of strains to take up the drug, indicating that susceptibility to PZA in mycobacteria requires both the presence of a functional PZase and a PZA transport system. No correlation was observed between the occurrence and cellular location of PZase and of nicotinamidase in the strains examined, suggesting that one or both amides can be hydrolysed by other mycobacterial amidases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10411262     DOI: 10.1099/13500872-145-6-1359

Source DB:  PubMed          Journal:  Microbiology        ISSN: 1350-0872            Impact factor:   2.777


  25 in total

1.  Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing with Mycobacterium tuberculosis.

Authors:  A P Davies; O J Billington; T D McHugh; D A Mitchison; S H Gillespie
Journal:  J Clin Microbiol       Date:  2000-10       Impact factor: 5.948

2.  Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections.

Authors:  Zahoor Ahmad; Mostafa M Fraig; Gregory P Bisson; Eric L Nuermberger; Jacques H Grosset; Petros C Karakousis
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

3.  Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.

Authors:  Anthony D Baughn; Jiaoyu Deng; Catherine Vilchèze; Angelica Riestra; John T Welch; William R Jacobs; Oren Zimhony
Journal:  Antimicrob Agents Chemother       Date:  2010-09-27       Impact factor: 5.191

4.  Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs.

Authors:  Tawanda Gumbo; Chandima S W Siyambalapitiyage Dona; Claudia Meek; Richard Leff
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

5.  Nonresponding osteomyelitis in a two-year-old boy.

Authors:  Sarah Khan; Jennifer Stimec; Ian Kitai
Journal:  CMAJ       Date:  2015-04-27       Impact factor: 8.262

6.  Esters of Pyrazinoic Acid Are Active against Pyrazinamide-Resistant Strains of Mycobacterium tuberculosis and Other Naturally Resistant Mycobacteria In Vitro and Ex Vivo within Macrophages.

Authors:  David Pires; Emília Valente; Marta Filipa Simões; Nuno Carmo; Bernard Testa; Luís Constantino; Elsa Anes
Journal:  Antimicrob Agents Chemother       Date:  2015-10-05       Impact factor: 5.191

7.  Comprehensive multicenter evaluation of a new line probe assay kit for identification of Mycobacterium species and detection of drug-resistant Mycobacterium tuberculosis.

Authors:  Satoshi Mitarai; Seiya Kato; Hideo Ogata; Akio Aono; Kinuyo Chikamatsu; Kazue Mizuno; Emiko Toyota; Akiko Sejimo; Katsuhiro Suzuki; Shiomi Yoshida; Takefumi Saito; Ataru Moriya; Akira Fujita; Shuko Sato; Tomoshige Matsumoto; Hiromi Ano; Toshinori Suetake; Yuji Kondo; Teruo Kirikae; Toru Mori
Journal:  J Clin Microbiol       Date:  2012-01-11       Impact factor: 5.948

8.  Expression of Mycobacterium smegmatis pyrazinamidase in Mycobacterium tuberculosis confers hypersensitivity to pyrazinamide and related amides.

Authors:  H I Boshoff; V Mizrahi
Journal:  J Bacteriol       Date:  2000-10       Impact factor: 3.490

9.  Molecular epidemiological study of pyrazinamide-resistance in clinical isolates of mycobacterium tuberculosis from South India.

Authors:  Muthuraj Muthaiah; Sridharan Jagadeesan; Nisha Ayalusamy; Manupriya Sreenivasan; Sambamurthy Sangamesvara Prabhu; Usharani Muthuraj; Kamatchiyammal Senthilkumar; Saroja Veerappan
Journal:  Int J Mol Sci       Date:  2010-07-07       Impact factor: 5.923

10.  Multicenter evaluation of a nonweekend reading schedule for radiometric pyrazinamide susceptibility testing of Mycobacterium tuberculosis.

Authors:  B Madison; W Gross; I George; A Sloutsky; G Washabaugh; B Robinson-Dunn; H Lipman; B Metchock; G Mazurek; J Ridderhof
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.